From: FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis
Variable | ER-positive tumours | ER-negative tumours | ||||
---|---|---|---|---|---|---|
 | Hazard ratio | 95% confidence interval | P value | Hazard ratio | 95% confidence interval | P value |
Disease-free interval | Â | Â | Â | Â | Â | Â |
   Gradea | 1.387 | 1.027–1.874 | 0.033 | 1.001 | 0.637–1.574 | 0.996 |
   Tumour size ≥1.5 cmb | 1.551 | 0.926–2.595 | 0.095 | 2.348 | 1.092–5.052 | 0.029 |
   Positive lymph node stage | 1.407 | 0.879–2.252 | 0.155 | 2.597 | 1.563–4.315 | 0.000 |
   FGFR1 amplification | 2.250 | 1.184–4.274 | 0.013 | 1.104 | 0.440–2.774 | 0.833 |
Overall survival | Â | Â | Â | Â | Â | Â |
   Gradea | 2.600 | 1.471–4.594 | 0.001 | 1.673 | 0.731–3.829 | 0.223 |
   Tumour size ≥1.5 cmb | 2.124 | 0.792–5.697 | 0.134 | 2.594 | 0.911–7.387 | 0.074 |
   Positive lymph node stage | 1.973 | 0.953–4.083 | 0.067 | 5.124 | 2.646–9.924 | 0.000 |
   FGFR1 amplification | 3.389 | 1.374–8.358 | 0.008 | 1.278 | 0.450–3.624 | 0.645 |